Colorectal cancer (CRC) is among the most frequent cancers and is associated with high
mortality particularly when being diagnosed in advanced stages. Although several …

Numerous molecular processes conduct epigenetic regulation of protein transcription to
maintain cell specification. In this review, we discuss molecular mechanisms of the …

Our recent work has shown that DCAF1 (also known as VprBP) is overexpressed in colon
cancer and phosphorylates histone H2AT120 to drive epigenetic gene inactivation and …

Disruption of EZH2–embryonic ectoderm development (EED) protein–protein interaction
(PPI) is a new promising cancer therapeutic strategy. We have previously reported the …

EZH2 is a core component of the polycomb repressive complex 2 (PRC2), which catalyzes
trimethylation of histone H3 lysine 27 (H3K27me3) and promotes carcinogenesis by …

Specific molecular biomarkers for predicting the transition from colorectal adenoma to
cancer have been identified, however, circular RNA (circRNA)-related signatures remain to …

Colorectal cancer (CRC) develops in part through the deregulation of different signaling
pathways, including activation of the WNT/β-catenin and PI3K/AKT pathways. Additionally …

Objective Salivary duct carcinoma (SDC) is a highly aggressive and uncommon tumor
arising not only de novo but also in pleomorphic adenoma. Androgen receptor (AR)-and …

BACKGROUND The carcinogenesis of colorectal cancer (CRC) involves many different
molecules and multiple pathways, and the specific mechanism has not been elucidated until …

EZH2 inhibitors (EZH2i), a class of small-molecule inhibitors that target EZH2 to exert anti-
tumor functions, have just been approved by the US Food and Drug Administration (FDA) in …